MedTrace Logo

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

NCT01058005 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2014-09-03

Study results available
· View outcomes & findings →

Summary

This was a multicenter, randomized, open-label, parallel-group, active-controlled study. Prior to randomization, participants were to have been treated with glatiramer acetate or interferon β-1a (44 μg). Participants were to be randomized to receive natalizumab, interferon β-1a 44 μg, or glatiramer acetate.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

BG00002 (natalizumab)

300 mg intravenous injection every 4 weeks

DRUG

interferon beta-1a

44 mcg subcutaneous injection 3 times per week

DRUG

glatiramer acetate

20 mg subcutaneous injection once daily

Sponsors & Collaborators

  • Elan Pharmaceuticals

    collaborator INDUSTRY

  • Biogen

    lead INDUSTRY

Principal Investigators

  • Medical Director · Biogen

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • United States
  • Australia
  • Canada
  • Czechia
  • Finland
  • France
  • Hungary
  • Italy
  • Latvia
  • Poland
  • Slovenia
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01058005 on ClinicalTrials.gov